ANABV
AnaptysBio, Inc. Common Stock When IssuedKey Statistics
About AnaptysBio, Inc. Common Stock When Issued
AnaptysBio, Inc. is a clinical-stage biotechnology company dedicated to advancing innovative antibody therapeutics targeting severe immunology and oncology diseases. Utilizing its proprietary technology platform, AnaptysBio develops a diverse portfolio of high-quality monoclonal antibodies designed to address significant unmet medical needs. The company's promising pipeline showcases several therapeutic candidates currently in clinical trials, underscoring its commitment to delivering cutting-edge treatments. With a focus on strategic collaborations and a robust development strategy, AnaptysBio is well-positioned to enhance patient outcomes through meaningful therapeutic advancements.
Fundamentals
| Revenue (TTM) | $234.60M |
| Gross Profit (TTM) | $98.63M |
| EBITDA | $48.45M |
| Operating Margin | 61.80% |
| Return on Equity | -24.50% |
| Return on Assets | 7.06% |
| Revenue/Share (TTM) | $8.16 |
| Book Value | $1.33 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 151.10% |
| Shares Outstanding | 0 |
| Float | $17.26M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Historical Volatility
Volatility is currently contracting
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ANABV and any ticker you trade — then tracks every position and per-strategy win rate.